FIELD: medicine; oncology.
SUBSTANCE: present invention relates to combined therapy of malignant tumors. That is ensured by introducing variant 4D5 chimeric antibody in combination with a molecule which specifically binds a cell surface receptor or a ligand thereof which regulates an immune control point. 4D5 antibody contains a variable light chain domain comprising the amino acid sequence SEQ ID NO: 4, and heavy chain, which contains a variant Fc-site exhibiting increased ADCC activity, wherein the heavy chain contains an amino acid sequence selected from a group consisting of SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 13. A molecule which specifically binds a cell surface receptor comprises a variant Fc region having at least one modification relative to the wild-type IgG1 Fc region or the IgG4 Fc region, wherein said variant Fc region of said molecule exhibits reduced ADCC activity with respect to a comparable molecule which contains wild-type IgG1 Fc region.
EFFECT: combined administration of said agents provides effective treatment of tumors expressing HER2/neu, including refractory to trastuzumab therapy.
28 cl, 7 tbl, 8 ex, 15 dwg
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL | 2017 |
|
RU2757394C2 |
SOLUBLE UNIVERSAL REINFORCING ADCC SYNTHETIC FUSED GENE, PEPTIDE TECHNOLOGY AND USE THEREOF | 2015 |
|
RU2725807C2 |
A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
Authors
Dates
2020-10-01—Published
2016-06-09—Filed